Business Context and Reporting Period
This Form 8-K Current Report was filed by Compass Therapeutics, Inc. on April 21, 2023. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Richard S. Lindahl, MBA, as a new Class III director, effective immediately. Mr. Lindahl, currently the CFO of Emergent BioSolutions, Inc., was also appointed as a member and chairman of the Audit Committee. The Board determined he is an independent director and qualifies as an "audit committee financial expert."
Compensation and Governance Details
- Cash Compensation: Mr. Lindahl will receive a $45,000 annual cash retainer for general Board service and an additional $10,000 for serving as Audit Committee chairman.
- Equity Award: He received an initial option award to purchase 50,000 shares of common stock at the closing price on the grant date.
- Vesting Schedule: The option grants vest monthly over a four-year period.
- Term: His term as a Class III director expires at the Company's 2023 annual meeting of stockholders.
Investor Verification Checklist
- Verify the independence status and "audit committee financial expert" designation of Richard S. Lindahl per Nasdaq Listing Rules.
- Confirm the total annual cash compensation ($55,000) and the specific vesting terms of the 50,000 share option grant.
- Review the indemnification agreement filed as Exhibit 10.4 to ensure consistency with existing director agreements.
- Monitor the impact of this appointment on the composition of the Audit Committee and Board independence.